Roundtable Roundup: Challenges of Treating Myelofibrosis
In separate live virtual events, James K. McCloskey II, MD, and Bart L. Scott, MD, polled participants on disease symptoms and bridging therapy options for a patient with primary myelofibrosis (PMF).
CASE SUMMARY
A man aged 62 years presented to his primary care physician (PCP) with symptoms of fatigue, night sweats, and increased bruising .
Medical history: type 2 diabetes, hypercholesterolemia, and hypertension
The PCP noticed lower hemoglobin concentration (11.0-9.5 g/dL) and platelet count (350,000-195,000/μL) from a previous annual physical examination.
Two months post PCP visit, a hematologic oncologist saw him.
Examination findings: spleen 5 cm below left costal margin, fatigue and night sweats worsening, bone pain
Hemoglobin: 9.1 g/dL
Platelet count: 135,000/μL
Bone marrow fibrosis of grade 2/3, with less than 5% bone marrow blasts
Molecular analysis showed a JAK2 V617F mutation with normal karyotype and no additional mutations .
He had a history of squamous cell carcinoma of the skin .
ECOG performance status: 2
Blood: 1% blasts by manual count/flow cytometry
Diagnosis: PMF
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
Nivolumab demonstrated superior efficacy in LA-HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib showed OS improvement in NSCLC, and sunvozertinib has been granted priority review status for NSCLC.
Read More
